Risk assessments for ovarian tumors are ever-evolving, as advances in diagnostic imaging and biomarker development pave the way. What are the current views on overian tumor risk assessment, and how should they be incorporated into clinical practice? Joining Dr. Matt Birnholz to address these questions is Dr. Fred Ueland, Professor of Obstetrics and Gynecology, and Director of Gynecologic Oncology at the University of Kentucky.
